Clementia Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Clementia Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Clementia Pharmaceuticals: 8 sponsored US clinical trials, none currently recruiting.

Clementia Pharmaceuticals sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Fibrodysplasia Ossificans Progressiva, with 2 trials.

Upper-quartile sponsor footprint

Clementia Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

NCT05039515
COMPLETED Phase 1

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

NCT04829773
TERMINATED Phase 2

An Efficacy and Safety Study of Palovarotene for the Treatment of MO

NCT03442985
COMPLETED Phase 3

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

NCT03312634
TERMINATED Phase 2

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

NCT02521792
COMPLETED

A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

NCT02322255
COMPLETED Phase 2

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

NCT02279095
COMPLETED Phase 2

An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

NCT02190747

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 5
Phase 3 1

Therapeutic Areas

Fibrodysplasia Ossificans Progressiva 2

How the Clementia Pharmaceuticals early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Fibrodysplasia Ossificans Progressiva (2 trials), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Clementia Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Clementia Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Clementia PharmaceuticalsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Clementia Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Clementia Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Clementia Pharmaceuticals page

8 registered trials is a research-attention snapshot, not an endorsement of Clementia Pharmaceuticals or any single study.

  • None of Clementia Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Fibrodysplasia Ossificans Progressiva is the condition Clementia Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Fibrodysplasia Ossificans Progressiva trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Clementia Pharmaceuticals pipeline card: 8 registered trials from official public datasets.Report a data error.